

## Clinical Policy: Ixekizumab (Taltz)

Reference Number: CP.PHAR.257

Effective Date: 09.01.16

Last Review Date: 05.23

Line of Business: Medicaid

[Coding Implications](#)  
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

Ixekizumab (Taltz<sup>®</sup>) is an interleukin-17A (IL-17A) antagonist.

### FDA Approved Indication(s)

Taltz is indicated for the treatment of:

- Patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy
- Adults with active psoriatic arthritis (PsA)
- Adults with active ankylosing spondylitis (AS)
- Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Taltz is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Axial Spondyloarthritis (must meet all):

1. Diagnosis of AS or nr-axSpA;
2. Prescribed by or in consultation with a rheumatologist;
3. Age  $\geq$  18 years;
4. Failure of at least TWO non-steroidal anti-inflammatory drugs (NSAIDs) at up to maximally indicated doses, each used for  $\geq$  4 weeks unless clinically significant adverse effects are experienced or all are contraindicated;
5. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
6. Dose does not exceed one of the following (a or b):
  - a. For AS: 160 mg at week 0, followed by maintenance dose of 80 mg every 4 weeks;
  - b. For nr-axSpA: 80 mg every 4 weeks.

**Approval duration: 6 months**

**B. Plaque Psoriasis** (must meet all):

1. Diagnosis of moderate-to-severe PsO as evidenced by involvement of one of the following (a or b):
  - a.  $\geq 3\%$  of total body surface area;
  - b. Hands, feet, scalp, face, or genital area;
2. Prescribed by or in consultation with a dermatologist or rheumatologist;
3. Age  $\geq 6$  years;
4. Member meets one of the following (a, b, or c):
  - a. Failure of a  $\geq 3$  consecutive month trial of methotrexate (MTX) at up to maximally indicated doses;
  - b. Member has intolerance or contraindication to MTX (*see Appendix D*), and failure of a  $\geq 3$  consecutive month trial of cyclosporine or acitretin at up to maximally indicated doses, unless clinically significant adverse effects are experienced or both are contraindicated;
  - c. Member has intolerance or contraindication to MTX, cyclosporine, and acitretin, and failure of phototherapy, unless contraindicated or clinically significant adverse effects are experienced;
5. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
6. Dose does not exceed one of the following (a – d):
  - a. For adults: 160 mg at week 0, 80 mg at weeks 2, 4, 6, 8, 10, and 12, followed by maintenance dose of 80 mg every 4 weeks;
  - b. For pediatric members weighing  $< 25$  kg: 40 mg at week 0, followed by 20 mg every 4 weeks;
  - c. For pediatric members weighing 25 – 50 kg: 80 mg at week 0, followed by 40 mg every 4 weeks;
  - d. For pediatric members weighing  $> 50$  kg: 160 mg (two 80 mg injections) at week 0, followed by 80 mg every 4 weeks.

**Approval duration: 6 months**

**C. Psoriatic Arthritis** (must meet all):

1. Diagnosis of PsA;
2. Prescribed by or in consultation with a dermatologist or rheumatologist;
3. Age  $\geq 18$  years;
4. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
5. Dose does not exceed one of the following (a or b):
  - a. PsA alone: 160 mg at weeks 0, followed by maintenance dose of 80 mg every 4 weeks;
  - b. PsA with coexistent PsO: 160 mg at week 0, 80 mg at weeks 2, 4, 6, 8, 10, and 12, followed by maintenance dose of 80 mg every 4 weeks.

**Approval duration: 6 months**

**D. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. All Indications in Section I** (must meet all):

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (*see Section III: Diagnoses/Indications for which coverage is NOT authorized*);
4. If request is for a dose increase, new dose does not exceed 80 mg every 4 weeks.

**Approval duration: 12 months**

**B. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.PMN.53 for Medicaid or evidence of coverage documents;
- B. Combination use with biological disease-modifying antirheumatic drugs (bDMARDs) or potent immunosuppressants, including but not limited to any tumor necrosis factor (TNF) antagonists [e.g., Cimzia<sup>®</sup>, Enbrel<sup>®</sup>, Humira<sup>®</sup> and its biosimilars, Simponi<sup>®</sup>, Avsola<sup>™</sup>, Inflectra<sup>™</sup>, Remicade<sup>®</sup>, Renflexis<sup>™</sup>], interleukin agents [e.g., Arcalyst<sup>®</sup> (IL-1 blocker), Ilaris<sup>®</sup> (IL-1 blocker), Kineret<sup>®</sup> (IL-1RA), Actemra<sup>®</sup> (IL-6RA), Kevzara<sup>®</sup> (IL-6RA), Stelara<sup>®</sup> (IL-12/23 inhibitor), Cosentyx<sup>®</sup> (IL-17A inhibitor), Taltz<sup>®</sup> (IL-17A inhibitor), Siliq<sup>™</sup> (IL-17RA), Ilumya<sup>™</sup> (IL-23 inhibitor), Skyrizi<sup>™</sup> (IL-23 inhibitor), Tremfya<sup>®</sup> (IL-23 inhibitor)], Janus kinase inhibitors (JAKi) [e.g., Xeljanz<sup>®</sup>/Xeljanz<sup>®</sup> XR, Cibinqo<sup>™</sup>, Olumiant<sup>™</sup>, Rinvoq<sup>™</sup>], anti-CD20 monoclonal antibodies [Rituxan<sup>®</sup>, Riabni<sup>™</sup>, Ruxience<sup>™</sup>, Truxima<sup>®</sup>, Rituxan Hycela<sup>®</sup>], selective co-stimulation modulators [Orencia<sup>®</sup>], and integrin receptor antagonists [Entyvio<sup>®</sup>] because of the additive immunosuppression, increased risk of neutropenia, as well as increased risk of serious infections.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

ACR: American College of Rheumatology	MTX: methotrexate
AS: ankylosing spondylitis	nr-axSpA: non-radiographic axial spondyloarthritis
FDA: Food and Drug Administration	PsA: psoriatic arthritis
IL-17A: interleukin-17A	PsO: plaque psoriasis
JAKi: Janus kinase inhibitors	

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
acitretin (Soriatane <sup>®</sup> )	<b>PsO</b> 25 or 50 mg PO QD	50 mg/day
cyclosporine (Sandimmune <sup>®</sup> , Neoral <sup>®</sup> )	<b>PsO</b> 2.5 – 4 mg/kg/day PO divided BID	4 mg/kg/day
methotrexate (Trexall <sup>®</sup> , Otrexup <sup>™</sup> , Rasuvo <sup>®</sup> , RediTrex <sup>®</sup> , Xatmep <sup>™</sup> , Rheumatrex <sup>®</sup> )	<b>PsO</b> 10 – 25 mg/week PO, IM, or SC or 2.5 mg PO Q12 hr for 3 doses/week	30 mg/week
NSAIDs (e.g., indomethacin, ibuprofen, naproxen, celecoxib)	<b>AS, nr-axSpA</b> Varies	Varies

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*\*Off-label*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients
- Boxed warning(s): none reported

*Appendix D: General Information*

- Definition of failure of MTX or DMARDs
  - Child-bearing age is not considered a contraindication for use of MTX. Each drug has risks in pregnancy. An educated patient and family planning would allow use of MTX in patients who have no intention of immediate pregnancy.
  - Social use of alcohol is not considered a contraindication for use of MTX. MTX may only be contraindicated if patients choose to drink over 14 units of alcohol per week. However, excessive alcohol drinking can lead to worsening of the condition, so patients who are serious about clinical response to therapy should refrain from excessive alcohol consumption.
- Examples of positive response to therapy may include, but are not limited to:
  - Reduction in joint pain/swelling/tenderness
  - Improvement in erythrocyte sedimentation rates/C-reactive protein (ESR/CRP) levels
  - Improvements in activities of daily living
- PsA: According to the 2018 American College of Rheumatology (ACR) and National Psoriasis Foundation guidelines, TNF inhibitors or oral small molecules (e.g., methotrexate, sulfasalazine, cyclosporine, leflunomide, apremilast) are preferred over other biologics (e.g., interleukin-17 inhibitors or interleukin-12/23 inhibitors) for treatment-naïve disease. TNF inhibitors are also generally recommended over oral small molecules as first-line therapy unless disease is not severe, member prefers oral agents, or TNF inhibitor therapy is contraindicated.
- AS and nr-axSpA: Although the 2019 ACR guidelines for AS recommend the use of TNF inhibitors over IL-17A antagonists such as Taltz or Cosentyx, this recommendation was based on “greater experience with TNF inhibitors and familiarity with their long-term safety and toxicity” rather than differences in efficacy.

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
PsO (with or without coexistent PsA)	<p><u>Adults:</u>  <u>Initial dose:</u> 160 mg (two 80 mg injections) SC at week 0, then 80 mg SC at weeks 2, 4, 6, 8, 10, and 12  <u>Maintenance dose:</u>                      80 mg SC every 4 weeks</p>	80 mg every 4 weeks

Indication	Dosing Regimen			Maximum Dose
	<u>Pediatrics between ages of 6 and 18 years:</u>			
	<b>Pediatric Patient's Weight</b>	<b>Starting Dose (Week 0)</b>	<b>Dose every 4 weeks (Q4W) Thereafter</b>	
	> 50 kg	160 mg (two 80 mg injections)	80 mg	
	25 to 50 kg	80 mg	40 mg	
	< 25 kg	40 mg	20 mg	
PsA, AS	<u>Initial dose:</u> 160 mg (two 80 mg injections) SC at week 0 <u>Maintenance dose:</u> 80 mg SC every 4 weeks			80 mg every 4 weeks
nr-axSpA	80 mg SC every 4 weeks			80 mg every 4 weeks

**VI. Product Availability**

- Single-dose prefilled autoinjector: 80 mg/mL
- Single-dose prefilled syringe: 80 mg/mL

**VII. References**

1. Taltz Prescribing Information. Indianapolis, IN: Eli Lilly and Company; July 2022. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/125521s024lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125521s024lbl.pdf). Accessed February 10, 2023.
2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2019;80:1029-72. Doi:10.1016/j.aad.201811.057.
3. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis.* 2020;79:700–712. Doi:10.1136/annrheumdis-2020-217159.
4. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. *American College of Rheumatology.* 2019; 71(1):5-32. Doi: 10.1002/art.40726.
5. Ward MM, Deodhar A, Gensler L, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis & Rheumatology.* 2019; 71(10):1599-1613. DOI 10.1002/ART.41042.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J3590, C9399	Injection, ixekizumab, 80 mg/mL

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2019 annual review: removed trial and failure requirement of conventional DMARDs (e.g., MTX)/NSAIDs for PsA per ACR/NPF 2018 guidelines; added HIM-Medical Benefit; references reviewed and updated.	03.05.19	05.19
Criteria added for new FDA indication: ankylosing spondylitis; Removed HIM-Medical Benefit line of business; updated preferred redirections based on SDC recommendation and prior clinical guidance: for AS and PsA, removed trial of etanercept and adalimumab; for PsO, removed trial of adalimumab.references reviewed and updated.	10.22.19	02.20
2Q 2020 annual review: no significant changes; added pediatric age extension from 18 years old to 6 years old for PsO; references reviewed and updated.	04.27.20	05.20
Criteria added for new FDA indication: nr-axSpA; added HCPCS code; references reviewed and updated.	06.26.20	11.20
2Q 2021 annual review: added additional criteria related to diagnosis of moderate-to-severe PsO per 2019 AAD/NPF guidelines specifying at least 3% BSA involvement or involvement of areas that severely impact daily function, updated dose limits to reflect pediatric limits; added combination of bDMARDs under Section; references reviewed and updated.	02.23.21	05.21
2Q 2022 annual review: for PsO, allowed phototherapy as alternative to systemic conventional DMARD if contraindicated or clinically significant adverse effects are experienced; reiterated requirement against combination use with a bDMARD or JAKi from Section III to Sections I and II; references reviewed and updated.	02.21.22	05.22
Template changes applied to other diagnoses/indications and continued therapy section.	10.11.22	
2Q 2023 annual review: no significant changes; updated off-label dosing for Appendix B; references reviewed and updated.	02.10.23	05.23

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical

practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed,



displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.